Abstract |
A bispecific monoclonal antibody (bs- MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate- binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse- antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.
|
Authors | R L Bolhuis, C H Lamers, S H Goey, A M Eggermont, J B Trimbos, G Stoter, A Lanzavecchia, E di Re, S Miotti, F Raspagliesi |
Journal | International journal of cancer. Supplement = Journal international du cancer. Supplement
(Int J Cancer Suppl)
Vol. 7
Pg. 78-81
( 1992)
ISSN: 0898-6924 [Print] United States |
PMID | 1428412
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal
- Interleukin-2
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibody Formation
- Cytotoxicity, Immunologic
- Female
- Humans
- Immunotherapy, Adoptive
- Interleukin-2
(therapeutic use)
- Lymphocyte Activation
- Ovarian Neoplasms
(therapy)
- T-Lymphocytes
(immunology)
|